Progressive disseminated aspergillosis in a bone marrow transplant recipient: response with a high-dose lipid formulation of amphotericin B

Clin Infect Dis. 2001 Mar 1;32(5):E94-6. doi: 10.1086/319208. Epub 2001 Feb 23.

Abstract

We present a case of progressive disseminated aspergillosis that involved multiple sites in a bone marrow transplant recipient with severe, chronic graft-versus-host disease. The patient failed to respond to treatment with a conventional dosage of a lipid formulation of amphotericin B (lifoAmB; 5 mg/kg/day) given alone or in combination with itraconazole, and he responded only to an aggressive strategy that included a very high dosage of lifoAmB (15 mg/kg/day) given in combination with itraconazole as well as a rapid reduction in immunosuppression. Despite the patient's abnormal baseline kidney function, the very high doses of lifoAmB were well tolerated and did not result in additional renal toxicity.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Amphotericin B / therapeutic use*
  • Antifungal Agents / therapeutic use*
  • Aspergillosis / drug therapy*
  • Aspergillosis / microbiology
  • Aspergillus fumigatus / isolation & purification*
  • Bone Marrow Transplantation / adverse effects*
  • Drug Therapy, Combination
  • Graft vs Host Disease / therapy
  • Humans
  • Itraconazole / therapeutic use
  • Male
  • Treatment Outcome

Substances

  • Antifungal Agents
  • liposomal amphotericin B
  • Itraconazole
  • Amphotericin B